Ovarian Cancer – Cell and Gene Therapies 15-Market Assessment and Forecast to 2031
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Ovarian Cancer–Cell and Gene Therapies 15-Market Report Overview
The total market value for the 15M, which includes both CGTs and established/traditional ovarian cancer therapies was $3.2B in 2021. The increasing number of ovarian cancer cases will drive market growth during the forecast period.
Ovarian Cancer–Cell and Gene Therapies 15-Market Outlook, 2021-2031 ($ Billion)
Buy the Full Report to Know More about the Ovarian Cancer–Cell and Gene Therapies 15-Market Forecast
The ovarian cancer–cell and gene therapies 15-market research report offers a comprehensive insight into the market through 2032. The report provides an overview of the disease including epidemiology, symptoms, diagnosis, disease management, countries where the disease is prevalent, and leading players associated with the market.
| Market Size (2021) | $3.2 billion |
| Forecast Period | 2021-2031 |
| Key Regions | · APAC
· Europe · Middle East · North America |
| Leading Players | · Triumvira Immunologics
· Gradalis · Adaptimmune Therapeutics · ICON · Sarah Cannon Research Institute |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Ovarian Cancer–Cell and Gene Therapies 15-Market Dynamics
Innovative biologics and small molecule inhibitors for novel targets could impede the progress of CGTs. However, high level of unmet need in patients resistant to platinum, especially in the third and fourth lines of therapy will propel market growth in the coming years.
Ovarian Cancer–Cell and Gene Therapies 15-Market Analysis by Treatment
- The clinical-stage pipeline for ovarian cancer is largely dominated by small molecules, which are widely recognized as the most frequently utilized treatment option, either alone or in combination, for this condition.
- Ovarian cancer presents with unmet needs that are yet to be addressed sufficiently to date. Current treatment options cannot overcome acquired resistance to platinum-based chemotherapy, which appears as a big area of unmet need for drug developers to address.
Buy Full Report for More Insights into the Ovarian Cancer–Cell and Gene Therapies 15-Market Treatment
Ovarian Cancer–Cell and Gene Therapies 15-Market Segmentation by Regions
North America had the highest sales in 15MM in the ovarian cancer – cell and gene therapies 15-market.
A few of the key regions in the market are APAC, Europe, Middle East, and North America.
Ovarian Cancer–Cell and Gene Therapies 15-Market Analysis by Regions, 2021 (%)
Buy Full Report for More Regional Insights into the Ovarian Cancer–Cell and Gene Therapies 15-Market
Ovarian Cancer–Cell and Gene Therapies 15-Market -Competitive Landscape
The majority of early phase trials in ovarian cancer are basket/indication prioritization trials, which cannot qualify a company as a major player in the field. Further, Genelux Corporation, despite being considered a future player due to having the most promising pipeline CGT therapy, only has one trial (Phase III) ongoing in ovarian cancer.
A few of the major players in the ovarian cancer–cell and gene therapies 15-market are:
- Triumvira Immunologics
- Gradalis
- Adaptimmune Therapeutics
- ICON
- Sarah Cannon Research Institute
Ovarian Cancer–Cell and Gene Therapies 15-Market Analysis by Companies
Buy the Full Report to Know More about Companies in the Ovarian Cancer–Cell and Gene Therapies 15-Market
Ovarian Cancer–Cell and Gene Therapies 15-Country Outlook (Value, $ Billion, 2021-2031)
- APAC
- Europe
- Middle East
- North America
Scope
Ovarian cancer cell and gene therapy market research includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and pipeline therapies with established mechanisms of action and cell & gene therapies by class, including early to late clinical-stage pipeline products, with a launch date assessment by the market for ovarian cancer.
PBF sales data for the 8MM, this report contains sales forecast extrapolations for an additional seven geographical markets (7M), totaling 15 markets (15M). These sales forecast extrapolations leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases.
Key Highlights
Report deliverables include a:
- PowerPoint report and Excel-based forecast model
- Forecast includes 8 countries
- Forecast covers 2021-2031
- Seven markets are extrapolated, obtaining a 15-market value for all Ovarian Cancer therapeutics.
Reasons to Buy
- Obtain cell & gene therapy sales forecasts across multiple regions
- Gain insight into promising early-stage approaches
Our indication-specific forecast models answer questions such as:
- What is the target patient pool for cell & gene therapies in each cancer indication?
- Which patient groups are more likely to receive these therapies?
- What does the cell & gene therapy clinical-stage pipeline look like in each cancer indication
- What is the anticipated breakdown between autologous and allogeneic cell therapies?
- When will cell & gene therapies launch in each market?
- What is the total market value projected for the forecast end, in 2031?
Genelux
Gradalis
Table of Contents
Frequently asked questions
-
What was the ovarian cancer–-cell and gene therapies 15-market size across the 8MM in 2021?
The total market value for the 15M, which includes both CGTs and established/traditional ovarian cancer therapies was $3.2B in 2021.
-
Which region had the highest sales in the ovarian cancer– cell and gene therapies 15-market?
North America held the highest sales in the ovarian cancer– Cell and Gene Therapies 15-market across the 8MM in 2021.
-
Who are the leading players operating in the ovarian cancer– cell and gene therapies 15-market?
A few of the major players in the ovarian cancer– cell and gene therapies 15-market are Triumvira Immunologics, Gradalis, Adaptimmune Therapeutics, ICON, Sarah Cannon Research Institute among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Ovarian Cancer reports


